-
Reata Pharmaceuticals – Omaveloxolone Update #4
Reata announces that the FDA has asked the company to request a Pre-NDA Meeting for Omaveloxolone for the treatment of Friedreich’s Ataxia.
The FDA’s request for a Pre- NDA meeting demonstrates the power of the community’s unified voice. The FDA is demonstrating flexibility, being open to additional data analysis, and considering the patient voice in the drug development process. We are also grateful to Reata Pharmaceuticals for their steadfast commitment to the omaveloxolone program in FA. FARA looks forward to working with both Reata and the FDA in the next steps of the process and keeping the community informed.
Read the full press release here:
Log in to reply.